Testing rifaximin for heart failure with preserved pumping
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests whether the antibiotic rifaximin (taken by mouth) can improve heart function in people with a type of heart failure where the heart pumps well but is still weak (HFpEF). Rifaximin might help by changing the bacteria in your gut.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old and have a body mass index (BMI) of 25 or higher (overweight range)
- You have heart failure with preserved ejection fraction (HFpEF) — meaning your heart pumps normally but you still have heart failure symptoms
- A blood test shows elevated NT-proBNP (a marker of heart strain) at 125 pg/mL or higher
- You also have one of these heart changes: thickened heart wall (LVH), enlarged left atrium (LAE), or diastolic dysfunction (stiff heart muscle)
- You do not have a recent serious condition like stomach bleeding or heart attack
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HRS-1893 for people with heart failure with preserved ejection fraction (HFpEF). It aims to see if the drug can improve symptoms and quality of life.
This trial tests if rifaximin, a gut-targeted antibiotic, can help people with fatty liver disease who also have metabolic problems like obesity or diabetes. You need a recent fatty liver diagnosis and a liver fat level of at least 8% on an MRI scan.
This trial tests whether a gut-targeting antibiotic called rifaximin changes the gut microbiome (gut bacteria) and affects emotion. It is looking for healthy men so any mood or gut changes can be more clearly linked to the study treatment.
This study tests whether adding a probiotic supplement to the antibiotic rifaximin improves treatment for people with irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO), a condition where too many bacteria grow in the small intestine. If you have IBS and SIBO, this combination might help reduce your symptoms.
This trial tests if rifaximin, a gut medication, can help reduce liver fat in people with metabolic fatty liver disease. It may be an option if you have at least one metabolic risk factor and a certain amount of liver fat.
This trial tests a medication called rifaximin (an antibiotic that works in the gut) to see if it reduces bloating in people with functional bowel disorders like IBS or chronic constipation. If you have stubborn bloating despite treatment, this could be a new option to help you feel better.
Hear when a new Heart Failure With Preserved Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.